QURE Jan 2023 25.000 put
| Previous close | 8.58 |
| Open | 6.30 |
| Bid | 6.90 |
| Ask | 7.60 |
| Strike | 25.00 |
| Expiry date | 2023-01-20 |
| Day's range | 6.30 - 9.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 54 |
- Motley Fool
Why uniQure Stock Is Crashing Today
Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning. Investors weren't all that interested in uniQure's financial results.
- Zacks
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ~ Announced postponement of AMT-130 higher-dose procedures due to recent suspected unexpected severe adverse reactions at this dose; Lower-dose procedures are not affected and no impact is expected on anticipated data readout
